CA 19-9 has been shown to be elevated in some patients with cancer tumors. CA 19-9 has been reported as positive in 70% to 80% of pancreatic carcinomas, 50% to 60% of gastric cancers, 60% of hepatobiliary cancer, 30% of colorectal cancer.and few lung.breast or prostate cancers. Serum levels may differentiate pancreatic cancer from pancreatitis. The test may also be positive in patients with non-neoplastic disease, particularly inflammatory disease of the bowel.cirrhosis ,and autoimmune conditions including rheumatoid arthritis (33%), systemic lupus erythematosus (32%), and scleroderma (33%).
Price: $99.00 |
